{"entity":{"id":"nct07570173","kind":"trial","name":"A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)","aka":[],"tldr":"A phase 2/3 trial testing MK-1045 in acute lymphoblastic leukaemia, now recruiting.","summary":"A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukaemia (MK-1045-005) is a phase 2/3 interventional study registered as NCT07570173, led by Merck Sharp & Dohme, and recruiting on the registry. Official title: A Phase 2/3, Randomised, Open-Label, Comparison Study of MK-1045 Versus Blinatumomab in Participants With Relapsed or Refractory CD19+ B-Cell Acute Lymphoblastic Leukaemia (B-ALL). Planned enrolment is 340 participants (estimated). The study started in 2026-05-18 and primary completion is expected in 2033-10-18. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT07570173","url":"https://clinicaltrials.gov/study/NCT07570173"}],"tags":["ctgov-ingest"],"related":[],"cancers":["all-leukemia"],"sections":[],"technologies":[],"targets":[],"drugs":["mk-1045","siltuximab"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07570173","phase":"2/3","setting":"A Phase 2/3, Randomized, Open-Label, Comparison Study of MK-1045 Versus Blinatumomab in Participants With Relapsed or Refractory CD19+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)","sponsor":"Merck Sharp & Dohme","started":"2026-05-18","startedType":"actual","enrolled":340,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07570173/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"}],"drug":[{"id":"mk-1045","kind":"drug","name":"MK-1045","route":"/drugs/mk-1045/"},{"id":"siltuximab","kind":"drug","name":"Siltuximab","route":"/drugs/siltuximab/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}